×
CorMedix Inc Common Stock Net 2011-2025 | CRMD
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
CorMedix Inc common stock net from 2011 to 2025. Common stock net can be defined as the value of common equity ownership.
View More
CorMedix Inc Common Stock Net 2011-2025 | CRMD
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
CorMedix Inc common stock net from 2011 to 2025. Common stock net can be defined as the value of common equity ownership.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$243.4B
Amgen (AMGN)
$156.3B
Gilead Sciences (GILD)
$147.7B
Vertex Pharmaceuticals (VRTX)
$100.1B
Bristol Myers Squibb (BMY)
$97.3B
CSL (CSLLY)
$85B
GSK (GSK)
$80B
Regeneron Pharmaceuticals (REGN)
$60B
Alnylam Pharmaceuticals (ALNY)
$58B
Argenex SE (ARGX)
$39.9B
BioNTech SE (BNTX)
$27.1B
Insmed (INSM)
$27B
Royalty Pharma (RPRX)
$20.5B
Biogen (BIIB)
$19.8B
Incyte (INCY)
$16.8B
Illumina (ILMN)
$15.4B
Genmab (GMAB)
$14.7B
Genmab (GNMSF)
$14.3B
Ascendis Pharma (ASND)
$11.7B
BioMarin Pharmaceutical (BMRN)
$11.1B
QIAGEN (QGEN)
$10.9B
Moderna (MRNA)
$10.4B
Exelixis (EXEL)
$10.4B
Swedish Orphan Biovitrum (BIOVF)
$10.3B
Verona Pharma American Depositary Share (VRNA)
$9B
Exact Sciences (EXAS)
$8.5B
Bio-Techne Corp (TECH)
$8.4B
Blueprint Medicines (BPMC)
$8.3B
Roivant Sciences (ROIV)
$8B
Halozyme Therapeutics (HALO)
$7.7B